Drugs / JYP0015
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06895031 | Mar 2025 → Mar 2026 overdue | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Guangzhou JOYO Pharma Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JYP0015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06895031 ↗ |
| Action | Inhibit | “JYP0015 is a potent, orally bioavailable pan-RAS inhibitor” NCT06895031 ↗ |
| Route | Oral | “The drug will be administered orally” NCT06895031 ↗ |
| Target | HRAS | “JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms.” NCT06895031 ↗ |
| Target | KRAS | “JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms.” NCT06895031 ↗ |
| Target | NRAS | “JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms.” NCT06895031 ↗ |